Fierce Pharma May 3, 2024
Shortly after Novo Holdings’ parent company elected to resubmit paperwork around the investment firm’s proposed $16.5 billion buyout of CDMO giant Catalent, the U.S. Federal Trade Commission (FTC) has teed up a further extension on the deal’s review period.
Catalent and the Novo Nordisk Foundation on Thursday received requests for additional documents and information on the proposed deal from the FTC as part of what’s known as a “second request,” Catalent said in a Friday securities filing. The Novo Nordisk Foundation acts as parent to both Novo Holdings and drugmaker Novo Nordisk.
The FTC’s second request imposes an additional waiting period of up to 30 days for the agency to review the deal from the time the Novo Nordisk Foundation...
Today's Sponsors
Today's Sponsor